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Abstract
Background: Chemotherapy heavily relies on apoptosis to kill breast cancer (BrCa) cells. Many breast tumors
respond to chemotherapy, but cells that survive this initial response gain resistance to subsequent treatments. This
leads to aggressive cell variants with an enhanced ability to migrate, invade and survive at secondary sites.
Metastasis and chemoresistance are responsible for most cancer-related deaths; hence, therapies designed to
minimize both are greatly needed. We have recently shown that CCR9-CCL25 interactions promote BrCa cell
migration and invasion, while others have shown that this axis play important role in T cell survival. In this study
we have shown potential role of CCR9-CCL25 axis in breast cancer cell survival and therapeutic efficacy of cisplatin.
Methods: Bromodeoxyuridine (BrdU) incorporation, Vybrant apoptosis and TUNEL assays were performed to
ascertain the role of CCR9-CCL25 axis in cisplatin-induced apoptosis of BrCa cells. Fast Activated Cell-based ELISA
(FACE) assay was used to quantify In situ activation of PI3K
p85,A k t
Ser473, GSK-3b
Ser9 and FKHR
Thr24 in breast cancer
cells with or without cisplatin treatment in presence or absence of CCL25.
Results: CCR9-CCL25 axis provides survival advantage to BrCa cells and inhibits cisplatin-induced apoptosis in a
PI3K-dependent and focal adhesion kinase (FAK)-independent fashion. Furthermore, CCR9-CCL25 axis activates cell-
survival signals through Akt and subsequent glycogen synthase kinase-3 beta (GSK-3b) and forkhead in human
rhabdomyosarcoma (FKHR) inactivation. These results show that CCR9-CCL25 axis play important role in BrCa cell
survival and low chemotherapeutic efficacy of cisplatin primarily through PI3K/Akt dependent fashion.
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Introduction
Breast cancer (BrCa) is second leading cause of cancer
related deaths among women after lung cancer [1]. It is
estimated that 207,090 women will be diagnosed with
BrCa in 2010 and 39,480 will die from this disease in
United States [1]. Cisplatin and its analogues have been
widely used to treat human cancers including BrCa [2].
Unfortunately, many tumors become resistant to cispla-
tin, which is characterized by decreased susceptibility to
apoptosis. Cancer cells develop resistance to chemother-
apy primarily by inactivating apoptotic factors and/or
enhancing cell survival pathways [3].
Chemokines are a group of small proteins (8 - 10
kDa), structurally related molecules that regulate traf-
ficking of lymphocytes through interactions with a sub-
set of seven-transmembrane G-protein coupled
receptors [4]. To this end, we have recently shown sig-
nificantly higher expression of CCR9 in ovarian and
prostate cancer cell lines and tumors [5,6]. CCR9-
CCL25 interactions known to support T cells survival
during thymic maturation by inhibiting apoptosis
through Akt/protein kinase B activation, which is PI3K-
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anti-apoptotic and survival pathway plays a crucial role
in cisplatin resistance [9]. FAK has also been shown to
support anti-apoptotic mechanisms through Akt signal-
ing [10]. Chemokine receptors may also aggregate with
integrins following stimulation to promote FAK
phosphorylation.
This study investigates the role of CCR9-CCL25 inter-
actions and requirement for PI3K and FAK activation in
BrCa cell survival and cisplatin resistance. We show for
the first time that CCR9-CCL25 interactions provide
protection from cisplatin-induced BrCa cell death. We
also show that CCR9-CCL25 interaction promotes cell
proliferation and upregulated anti-apoptotic signaling,
which is mediated by the PI3K/Akt survival pathway,
independent of FAK. These studies suggest that the
expression of functional CCR9 may facilitate BrCa cell
survival and low chemotherapeutic response.
Materials and methods
Cell culture
Human BrCa cell lines, MDA-MB-231 and MCF-7, were
obtained from ATCC. These cells were cultured in
RPMI-1640 media (Mediatech, Inc.) supplemented with
10% fetal bovine serum (FBS; Sigma) at 37°C with 5%
CO2. Prior to each experiment, cells were cultured for
24 hours in RPMI 1640 with 1% FBS to serum starve
the cells.
Bromodeoxyuridine incorporation assay
BrCa cells (10
5) were cultured alone or with 100 ng/mL
CCL25 + 1 μg/mL of isotype control antibody or 100
ng/mL CCL25 + 1 μg/mL anti-CCR9 antibody (clone
112509, R&D Systems) for 24 hours with 0, 0.1, 1, 2, 5,
10, 25, or 50 μg/mL of cisplatin. Incorporation of bro-
modeoxyuridine (BrdU) into newly synthesized DNA
permits indirect detection of rapidly proliferating cells.
Hence, this assay was used according to manufacturer’s
instructions to estimate BrCa cell growth. Briefly, cells
were treated with BrdU for 18 hours at 37°C. Media
containing labelling solution was removed and cells
were washed twice with media containing 10% serum.
BrCa cells were fixed with 200 μL of fixative solution
for 30 minutes at ~25°C and washed as before. Next,
cells were incubated with 100 μL of nuclease solution
for 30 minutes at 37°C and washed 3 times. Subse-
quently, 100 μL of anti-BrdU antibody was added, incu-
bated for 30 minutes at 37°C, and washed 3 times. BrdU
incorporation by BrCa cells was detected by peroxidase
substrate reaction. After the extinction of this reaction,
the samples were measured in a micro plate reader at
405 nm with a reference wavelength at approximately
490 nm.
Vybrant apoptosis assay
BrCa cells were cultured in RPMI-1640 media with 5
μg/ml of cisplatin (IC
50), along with no additions or 100
ng/mL of CCL25 or 1 μg/mL of anti-CCR9 Ab or 100
ng/mL of CCL25 plus 1 μg/mL of anti-CCR9 Ab for 24
hours. The cells were harvested and washed in ice-cold
PBS. Cells (10
5 cells/mL) were stained with Annexin-V
and propidium iodide (PI) using the Vybrant apoptosis
assay Kit #3 (Invitrogen) according to manufacturer’s
protocol. The stained cells were analyzed by flow cyto-
metry using UV/488 nm dual excitation and measuring
the fluorescence emission at approximately 530 nm and
575 nm.
Terminal Transferase dUTP Nick End Labeling (TUNEL)
Assay
BrCa cells were cultured with 0 or 5 μg/ml (IC
50)o fc i s -
platin, along with no additions or 100 ng/mL of CCL25
plus 1 μg/mL of anti-CCR9 or isotype control antibodies
for 24 hours. Apoptosis was measured by TUNEL assay
(Millipore) according to the manufacturer’s instructions.
Briefly, following treatment the cells were fixed with 4%
paraformaldehyde in 0.1 M NaH2PO4,p H7 . 4f o r1 5
minutes. After washing in PBS three times, the cells
were incubated with 0.05% Tween-20 in PBS for 15
minutes. After washing in PBS, the cells were incubated
with TdT end-labelling cocktail for 60 minutes. Termi-
nation buffer was added to stop the reaction. After
washing 4 times in PBS, cells were blocked for 20 min-
utes and stained with avidin-fluorescein isothiocyanate
(FITC) solution for 30 minutes. After washing with PBS
3 times, fluorescence plate reader quantified the fluores-
cence of TUNEL positive cells.
Fast activated cell-based ELISA (FACE)
The levels of total and active (phosphorylated) PI3K
p85,
Akt
Ser473,G S K - 3 b
Ser9,a n dF K H R
Thr24 were quantified
using Fast Activated Cell-based ELISA (FACE) assays
(Active Motif) according to the manufacturer’si n s t r u c -
tions. Briefly, cells were cultured in 96-well plates one
day prior to manipulation. BrCa cells were cultured in
serum-free media with 0 or 5 μg/ml of cisplatin or 100
ng/ml of CCL25 or 5 μg/mL of cisplatin with 100 ng/
mL of CCL25 for 24 hours. In addition, cells were trea-
ted with or without kinase inhibitors of PI3K (wortman-
nin; Sigma) and FAK (PF-573, 228;Pfizer).
Statistics
T h ed a t aw e r ec o m p a r e du s i n gat w o - t a i l e dS t u d e n t ’st
test and expressed as the mean ± SE. The results were
analyzed using the Statview II program (Abacus Con-
cepts, Inc., Berkeley CA) and were labeled statistically
significant if p values were < 0.01.
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Effects of CCL25 on cisplatin-induced growth inhibition
CCL25 significantly enhanced the growth of MDA-MB-
231 cells in comparison to untreated (cisplatin-free
BrCa) cells (Figure 1). While cisplatin concentrations of
≤ 1 μg/mL had no major effect on either CCL25-treated
or untreated BrCa cell growth, 2 μg/mL of cisplatin
reduced cell proliferation of untreated, but not CCL25-
treated cells. In fact, CCL25 significantly protected cis-
platin (< 5 μg/mL)-mediated growth inhibition. As the
concentration of cisplatin reached ≥ 10 μg/mL, the
effect of CCL25-mediated protection of cisplatin-
induced BrCa cell growth inhibition dissipated. Impor-
tantly, the significant increases of BrCa cell proliferation
and cisplatin-dependent growth inhibition caused by
CCL25 treatment was abrogated by CCR9 blockade.
CCL25-induced survival and cisplatin resistance of breast
cancer cells
Cisplatin treatment resulted in a ~5 fold increase in
apoptotic cells, relative to the untreated cells (Figure
2A). However, CCL25 significantly decreased the per-
centage of cisplatin-treated apoptotic cells, compared to
untreated or anti-CCR9 Ab treated cells. As with growth
inhibition, the decrease in the percentage of cisplatin-
induced apoptotic cells (or increase in cell survival)
afforded by CCL25 was abolished by CCR9 inhibition.
Apoptosis was also assessed under the same conditions
by TUNEL analysis (Figure 2B). BrCa cells treated with
cisplatin showed an increase in apoptosis as compare to
the untreated cells. However, similar cisplatin-treated
cells co-cultured with CCL25 displayed significantly low
apoptotic or TUNEL-positive events, which was abro-
gated after CCR9 blockade.
CCR9-CCL25-interactions lead to PI3K p85, Akt, GSK-3b
and FKHR activation
To identify the cellular signals involved in cisplatin
resistance mediated by CCR9-CCL25 interaction, in situ
PI3K p85, Akt, GSK-3b, and FKHR phosphorylation
levels were quantified by FACE assay. Cisplatin alone
had no significant effect on PI3K activity in comparison
to untreated cells (Figure 3A). CCL25 induced a rapid
increase in PI3Kp85 activation after 5 minutes, which
continued through 10 minutes in the presence or
absence of cisplatin. As expected, treatment with wort-
mannin, a PI3K inhibitor prevented CCL25-dependent
increases in PI3K activity in all samples. In contrast,
FAK inhibition had no effect on CCL25-mediated
PI3Kp85 phosphorylation. Interestingly, the immediate
increase in PI3K activation by CCL25 and cisplatin co-
cultured cells was moderately attenuated by FAK
inhibition.
The active (phosphorylated) to total Akt protein ratio
in BrCa cells not treated with CCL25 was approximately
2:1 (Figure 3B). Treatment with cisplatin alone had no
effect on Akt activity. There was a significant increase in
Akt phosphorylation ≥ 5 minutes after CCL25 treat-
ment. This CCL25-mediated Akt activity was partially
reduced by cisplatin co-culture. Wortmannin treated
cells were non-responsive to CCL25 stimulation, while
FAK inhibition had no effect on CCL25-mediated Akt
phosphorylation.
Activated Akt phosphorylates and inactivates the anti-
proliferative effects of GSK-3b. In the presence or
absence of cisplatin, CCL25 significantly increased GSK-
3b phosphorylation ≥ 5 minutes after treatment (Figure
4A). Wortmannin pre-treatment completely removed
this effect. However, FAK inhibition did not significantly
alter GSK-3b phosphorylation by CCL25 with or with-
out cisplatin co-culture.
Akt also inactivates FKHR through phosphorylation,
which leads to anti-apoptotic events or cell survival.
CCL25 induced a significant and rapid increase in
FKHR phosphorylation levels in either cisplatin-free or
-treated BrCa cells (Figure 4B). Wortmannin treatment
eliminated this effect. However, FAK-inhibition had no
effect on CCL25-mediated FKHR phosphorylation.
Discussion
According to the American Cancer Society, in 2010,
207,090 women will be diagnosed with BrCa and about
39,840 women will die from the disease [1]. Although
death rates have been declining since 1990, BrCa mor-
tality is high among African American women [11].
Figure 1 CCL25 inhibits cisplatin-induced reductions in cell
growth. MDA-MB-231 cells were cultured with 0 or 100 ng/ml of
CCL25 plus isotype control or anti-CCR9 Ab (1 μg/mL) for 24 hours,
along with increasing concentrations of cisplatin (0-50 μg/mL). Cell
proliferation was determined by BrdU incorporation in triplicate and
was repeated 3 times. Asterisks (*) indicate significant differences (p
< 0.01) between CCL25-treated and untreated BrCa cells.
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which is a common problem in the treatment of BrCa
[12,13]. Cisplatin and its analogues have been widely
used for treatment of human cancers, including
advanced BrCa [14-16]. However, resistance to cisplatin
represents a major obstacle in the effective management
of metastatic BrCa [17]. The balance between survival
and apoptotic signals in cancer cells determine the sen-
sitivity to chemotherapy and cancer cells develop resis-
tance to chemotherapies by inactivating apoptotic
factors and enhancing survival pathways [18]. However,
the factors that promote these remain incompletely
understood.
Chemokines direct the migration of leukocytes as well
as cancer cells [19,20] and they play a pivotal role in cell
survival [21]. Interactions between CXCR4 and its
ligand, CXCL12, promote the survival of breast [4], pan-
creatic cancers [22], and melanoma [23]. CCR9-CCL25
interactions also potentiate anti-apoptotic signaling to
immature, or double-positive T cells [24], and function
to retain single positive cells in the thymus until they
are fully mature and ready for export [7].
We have demonstrated that CCR9 is significantly
expressed by ovarian and prostate cells and play impor-
tant role in cell migration and invasion [25,26]. Here we
show that CCR9 also supports BrCa cell growth as well
Figure 2 Cisplatin-induced apoptosis. Panel A: MDA-MB-231 cells were cultured for 24 hours with 5.0 μg/ml of cisplatin with or without CCL25
(100 ng/mL) plus 1 μg/mL of anti-human CCR9 or isotype controls. Cells were stained with annexin V and propidium iodide (PI). Analysis by flow
cytometry of the stained cells distinguished apoptotic (annexin V positive) cells from viable (no fluorescence) and necrotic (PI positive) cells.
Asterisks (*) indicate significant differences (p < 0.01) between CCL25-treated and untreated BrCa cells. Panel B: MDA-MB-231 cells were cultured
for 24 hours with 5.0 μg/mL cisplatin or with 0 or 100 ng/ml of CCL25 plus anti-human CCR9 or isotype control Abs (1 μg/mL). Detection of
apoptotic cells was carried out using the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) method. Apoptotic
cells exhibited nuclear green fluorescence with a standard fluorescence filter set (520 ± 20 nm).
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cantly increases BrCa cell proliferation and cisplatin
resistance in a CCR9-dependent fashion.
It has been previously shown that CCR9 signaling
plays a role in immature T cell survival through PI3K
and Gai protein-dependent activation of Akt/protein
kinase B [27]. Downstream PI3K mediators directly
phosphorylate and activate Akt [28,29]. PI3K/Akt signal-
ing pathways are also frequently disturbed in many
human cancers and evidence suggests that chemokine
receptor signaling activates Akt [28,30]. Akt modulates
the function of numerous substrates involved in the reg-
ulation of cell survival, cell cycle progression and cellu-
lar growth. The PI3K/Akt pathway is also involved in
chemoresistance to cisplatin [9]. Phosphorylated Akt
promotes survival by phosphorylating and inactivating
pro-apoptotic factors, such as GSK-3b and or FKHR.
GSK-3b inhibition by Akt prevents phosphorylation of
b-catenin, which impedes its degradation; hence, it is
translocated to the nucleus. Once in the nucleus, b-
catenin combines with different transcription factors to
induce the expression of several genes, such as cyclin
D 1[ 2 9 ] .H e n c e ,A k t - m e d i a t e dp h o s p h o r y l a t i o no fG S K -
3b prevents the accumulation of cyclin D1, which is
needed to support cell cycle progression. FKHR transac-
tivates the expression of death activating proteins, such
as Fas ligand (FasL), Bim, and Bcl-6. Phosphorylating
FKHR1 at its threonine and serine residues prevents its
translocation to the nucleus and any associated gene
transcription [31].
Our studies strongly support the hypothesis that CCR9-
CCL25 signaling enhances BrCa cell growth and survival.
Specifically, we show that CCL25 induces the activation of
the PI3K/Akt pathway and phosphorylation of its down-
stream mediators, e.g., GSK-3b and FKHR. PI3K inhibition
completely abrogated CCL25-mediated and CCR9-depen-
dent cisplatin resistance, Akt, GSK-3b,a n dF K H Rp h o s -
phorylation. However, it was also plausible that other Akt-
activation pathways supported BrCa cell survival following
cisplatin (and CCL25) treatment. In this regard,
Figure 3 PI3K and Akt activation by CCR9-CCL25 interactions. MDA-MB-231 cells were tested for their ability to activate PI3K and Akt
following treatment with CCL25, cisplatin and specific kinase inhibitors (wortmannin and PF-573, 228). In situ total and active (phosphorylated)
PI3K and Akt levels were quantified by Fast Activated Cell-based ELISA (FACE) assay before (0 minutes) or after (5 or 10 minutes) CCL25
stimulation in the presence of cisplatin and kinase inhibitors.
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integrin clustering to potentially activate FAK, which is a
protein tyrosine kinase involved in cell proliferation,
migration and survival [32]. Activated FAK also interacts
with PI3K through integrin clustering [33]. However, our
findings show that FAK is not involved in CCL25-
mediated and CCR9-dependent Akt activation or subse-
quent GSK-3b and FKHR phosphorylation.
In support of our findings, a recent study has shown
that the PI3K/Akt signaling pathway is an important
event downstream of amphiregulin for the development
of cisplatin resistance in BrCa cells [34]. Taken together,
these results suggest that CCL25 treatment induces
BrCa cell survival and cisplatin resistance. We also show
that CCR9-dependent anti-apoptotic signaling involves
the PI3K/Akt pathway and phosphorylation of its down-
stream mediators, GSK-3b and FKHR - through CCR9
and PI3K/Akt, but independent of FAK, supporting our
hypothesis that CCR9-CCL25 interaction promotes
BrCa cell survival and resistance to cisplatin.
Conclusion
These results suggest that CCR9-CCL25 axis play signif-
icant role in BrCa cell survival and cisplatin resistance
primarily through PI3K/Akt dependent fashion.
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